Immix Biopharma : Presentation (IMMX Corporate presentation April 2026)

Published: 2026-05-03 11:39:04 ET IMMX

Published on 05/03/2026 at 11:39 am EDT

Global Leader in Relapsed/Refractory AL Amyloidosis

This presentation contains clinical data presented at ASH Dec 7, 2025

on pages 27 - 31

April 2026

The Moment Every Doctor and Family Dreads...

"There's Nothing More We Can Do."

In cases of relapsed/refractory AL amyloidosis,

that sentence is delivered to ~38,500 patients in the U.S.

Source: Incidence and prevalence: Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Amyloidosis Foundation. AL amyloidosis facts. Accessed October 2025. Incidence growth rate: Laires P et al, Prevalence, Incidence, and Characterization of LIGHT Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records (EHR). Blood 2023. Daratumumab: Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. Chakraborty R et al, Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study. AJH 2024. Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. ASCT: Bomsztyk J et al, Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective. Expert Review of Hematology 2022. Gustine J et al, Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. AJH 2022. Mayo staging: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024.

It's not good enough

to accept the status quo

I've been the doctor in that room. I've watched hope disappear, and I couldn't accept that months of suffering and subsequent death was "standard of care."

Ilya Rachman, MD PhD, Founder and CEO 5

When Your Immune System Becomes Your Killer

►

Normally, antibodies protect us like superheroes.

In AL amyloidosis, they go rogue,

turning into supervillains that flood organs with toxic light chains.

Painful and Unnecessary Months of Suffering

Healthy AL Amyloidosis

These toxic light chains clog up the heart, kidneys, and liver. Breathing becomes difficult, swelling begins, and even a short walk becomes challenging.

AL Amyloidosis: ~38,500 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs

NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE

Light chains produced by dysfunctional plasma cells in bone marrow

Light chains misfold and aggregate

Light chains deposit in organs, damaging organs

Bone marrow plasma cells

NXC-201 TARGETS BCMA RECEPTOR ON PLASMA CELLS, ELIMINATING SOURCE OF LIGHT CHAINS

BCMA

receptor

Light chains

Sheet of misfolded light chains

(amyloid)

Bone marrow

Circulation

dFLC (mg/L)

Source: Merlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Hemato 2022, 3(1), 47-62. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430; PMCID: PMC5965052. Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.

Kidney

Kidney failure

Elevated protein in the urine

Swelling of the limbs

Liver

Heart failure

Dangerous, irregular rhythms

Difficulty breathing

Low blood pressure

20mg/L

201 is to treat R/R

patients early enough to prevent reaching heart failure stage shown here

NXC-

Goal with

(immediately prior to

heart transplant)

Pre-existing heart failure

caused by AL Amyloidosis

Target tissues

Heart

Enlarged liver

Abnormal enzyme levels

The Current Paradigm is Failing: Standards of Care

12 PATIENT SERIES RELAPSED/REFRACTORY AL AMYLOIDOSIS RECEIVING SECOND LINE THERAPY

dFLC Level

Initial Dosing

11 out of 12

1 out of 12

Death due to Disease

Remission: No Symptoms

Days since treatment

There are no drugs approved in relapsed/refractory AL amyloidosis.

Current investigators' choice agents produce an unsatisfactory reduction in AL amyloidosis disease markers (dFLC) with a low (0-10%) complete response (CR) rate

Note: R/R AL investigator's choice therapies included: Dara-VCd, Dara-Vd, Dara-VRd, Dara-Dex, Dara-Cd, Dara-Pom-Dex, Bendamustine-Dex 9

Source: Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Normal dFLC: <10 mg/L.

The Toxic Current Last-Ditch Effort

Only one 4-drug combination is approved for newly diagnosed patients only. Once relapse hits, there's nothing FDA approved.

Doctors often resort to off label drug uses, despite their limited efficacy.

We're developing a breakthrough with the goal of changing that hopeless sentence

Our mission is simple:

Create medicines that work without destroying the patient.

The Science That Enables Our Platform

NXC-201 sterically-optimized CAR-T's "Digital Filter"…. …reduces non-specific activation

Ex-NCI/NIH Immix academic researchers ambitiously formulated a thesis: can cell therapy be expanded to a broader patient population, beyond cancer?

Result: Sterically-optimized NXC-201

Proprietary Optimized

CD3 - "CD3ζγ"

Delivers "Digital"

Intracellular Signaling

Proprietary Optimized

CD8 Hinge Flexibility

Reduces cytokine release

Sterically-optimized key construct modifications

Proprietary Optimized

COBRA Binder

Enhances Cytotoxicity

Enables High Expansion

CD8

Signaling Protein

COBRA Binder

CD8 Hinge

CD8

Transmembrane Protein

4-1BB

CD3ζγ

NXC-201 CAR-T

"Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range"

Source: M. Assayag, et al. Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis. 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT). Late Breaking Oral Presentation. Baltimore, MD. May, 2024. Feucht, M. Sadelain, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. 12

2019 Jan;25(1):82-88. doi: 10.1038/s41591-018-0290-5. Epub 2018 Dec 17. PMID: 30559421 PMCID: PMC6532069. O. Harush C. J. Cohen, et al. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. Haematologica. 2022 Oct 1;107(10):2395-2407. doi: 10.3324/haematol.2021.280169. PMID: 35354252 PMCID: PMC9521250. Adapted from PEGS 2021. Zanwar S, et al. Eyal Lebel et al., Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis. JCO. JCO-24-02252. DOI:10.1200/JCO-24-02252.

Extraordinary Results in Clinical Trials

Relapsed/refractory AL Amyloidosis - Market Situation Current Standards of Care NXC-201

0-10% complete response rate (standard of care)

75% complete response rate (ASH 2025)

Note: R/R AL current standard of care therapies included: Dara-VCd, Dara-Vd, Dara-VRd, Dara-Dex, Dara-Cd, Dara-Pom-Dex, Bendamustine-Dex

What that can mean for the patient…

Life becomes normal again.

A deep breath that reaches the bottom of the lungs. A walk that doesn't end at the mailbox.

A normal heartbeat again.

The Multi-Billion Dollar Economic Scale of This Impact

Existing reimbursement for BCMA CAR-T

MULTI-BILLION-DOLLAR MARKET

Source: Incidence and prevalence: Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Incidence growth rate: Laires P et al, Prevalence, Incidence, and Characterization of LIGHT Chain Amyloidosis in the USA: A Real-World Analysis Utilizing Electronic Health Records (EHR). Blood 2023. Daratumumab: Bellofiore C, et al. A real-life study of daratumumab

Note: Future management expected pricing represented on this page

combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. Chakraborty R et al, Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study. AJH 2024. Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 15

Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. ASCT: Bomsztyk J et al, Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective. Expert Review of Hematology 2022. Gustine J et al, Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-

year longitudinal study. AJH 2022. Mayo staging: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. According to WPS Health Solutions. Accessed 11/30/2025. According to CMS. Accessed 11/30/2025.

Our Unique Position to Transform This Disease

No approved therapies for relapsed/refractory patients.

RMAT + Orphan Drug Designation were granted to us in February 2025 and September 2023, respectively

2Q25

3Q25

4Q25

1Q26

2H 26

The Road Ahead

Phase 1 interim readout

ASCO oral presentation

Trial enrollment completion

NXC-201 U.S. NEXICART-2

Trial with Registrational Design

Prior

Final readout -

Topline Q3

Secured rights to NXC-201, N-GENIUS platform

FDA Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) Designation granted

Mentioned in New England Journal of Medicine (NEJM) AL Amyloidosis Review

Reported ex-U.S. NEXICART-1 AL Amyloidosis

data at ASGCT 2023, ASH 2023, ASGCT 2024,

ASH 2024, JCO published 2024

NEXICART-2 U.S. AL Amyloidosis clinical trial first 6 patients dosed; first patient at Memorial Sloan Kettering Cancer Center (met guidance)

Reported first 4 patients U.S. NEXICART-2 AL

Amyloidosis clinical data 4Q 2024 (met guidance)

Reported first 10 patients U.S. NEXICART-2 AL Amyloidosis clinical data Q2 2025 at ASCO 2025

Reported first 20 patients U.S. NEXICART-2 AL Amyloidosis clinical data Q4 2025 at ASH 2025

FDA Breakthrough Therapy Designation granted

NXC-201

Initial Clinical Data

in Other Serious

Diseases

Additional academic trial sites added

Other

Planned BLA Submission for

FDA Approval

The Road Ahead: Commercial

20 high-prescribing Sites in existing Immix clinical trial

Commercial launch plan in 1H 2027

The Road Ahead: Commercial

1188

… We believe that NXC-201 has potential beyond AL

CAR-T NXC-201 Targets Plasma Cells (antibody factories of the body)

AL Amyloidosis

Neurology

Hematology

Rheumatology

Vascular

Infiltrates and

damages heart

AL amyloid antibody deposits

Myasthenia Gravis

NMO Spectrum Disorder

Thrombotic thrombocytopenic purpura

Immune Thrombocytopenia

Systemic Lupus Erythematosus

Rheumatoid Arthritis

ANCA vasculitis

Light chain antibody fragments

D i s e a s e - c a u s i n g a n t i b o d i e

ANTIBODY FACTORY PLASMA CELL

( NXC- 201 therapeutic target)

Note: select indications noted above are for illustrative purposes only.

*Illustrative list of immune-mediated diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment 19

Source: MedicTests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial

interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non randozised phase 1/2a study. Lancet Neurol. 2023. McGlothlin J, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Front Immunol. 2023. Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol. 2019

A World Class Team Dedicated To Saving Lives

Ilya Rachman, MD, PhD

Chief Executive Office

David Marks, MBBS, PhD Chief Medical Officer

Gabriel Morris

Chief Financial Officer

Michael Grabow

Chief Commercial Officer

Amanda Squires Head of Clinical Operations

Oleg Evgrafov, Head of Quality

Denise Bruns Senior Regulatory Advisor

Mel Davis-Pickett, Head of Technical Development

Disclaimer

Immix Biopharma Inc. published this content on May 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 03, 2026 at 15:38 UTC.